We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.51B
1-Year Est. Return 164.17%
This Fund
S&P 500
This Quarter Est. Return
+27.41%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$2.58B
AUM Growth
-$40.8M
Cap. Flow
-$216M
Cap. Flow %
-8.36%
Top 10 Hldgs %
47.96%
Holding
78
New
7
Increased
10
Reduced
27
Closed
8

Top Buys

Rank Stock Value
1
SYK icon
Stryker
SYK
+$33.1M
2
VTYX
Ventyx Biosciences
VTYX
+$30.2M
3
PEN icon
Penumbra
PEN
+$28.7M
4
PLRX icon
Pliant Therapeutics
PLRX
+$27.5M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$26.3M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$151M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$72.8M
3
ARGX icon
argenx
ARGX
+$39.2M
4
SKIN icon
SkinHealth Systems
SKIN
+$38.9M
5
CNC icon
Centene
CNC
+$33M

Sector Composition

Rank Sector Weight
1 Healthcare 98.01%
2 Consumer Staples 0.96%
3 Industrials 0.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
1
Fate Therapeutics
FATE
$325M
$290M 11.26%
12,957,222
– –
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$227M 8.8%
21,719,191
-439,700
-2% -$4.9M
KRYS icon
3
Krystal Biotech
KRYS
$10B
$132M 5.14%
1,899,545
+1,000
+0.1% +$72.2K
ARGX icon
4
argenx
ARGX
$52.9B
$98.9M 3.83%
280,026
-105,792
-27% -$39.2M
PLRX icon
5
Pliant Therapeutics
PLRX
$66.3M
$94.2M 3.65%
4,508,204
+1,439,203
+47% +$27.5M
XENE icon
6
Xenon Pharmaceuticals
XENE
$6.38B
$85.6M 3.32%
2,370,614
+731,270
+45% +$26.3M
BEAM icon
7
Beam Therapeutics
BEAM
$2.71B
$84.5M 3.28%
1,772,987
-76,900
-4% -$4.39M
LIVN icon
8
LivaNova
LIVN
$4.35B
$78M 3.03%
1,536,362
-87,400
-5% -$5.19M
IGMS
9
DELISTED
IGM Biosciences
IGMS
$75.8M 2.94%
3,334,355
– –
ONEM
10
DELISTED
1Life Healthcare
ONEM
$70.1M 2.72%
4,087,625
-434,200
-10% -$6.82M
REPL icon
11
Replimune Group
REPL
$882M
$63M 2.44%
3,645,309
– –
KYMR icon
12
Kymera Therapeutics
KYMR
$9.14B
$62.6M 2.43%
2,876,637
+269,507
+10% +$7.1M
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$61M 2.37%
3,399,900
+1,881,000
+124% +$24.7M
CLDX icon
14
Celldex Therapeutics
CLDX
$2.78B
$55.8M 2.16%
1,985,151
-85,137
-4% -$2.61M
DCPH
15
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$55M 2.13%
2,973,029
+1,542,112
+108% +$24.2M
AKRO
16
DELISTED
Akero Therapeutics
AKRO
$54.2M 2.1%
1,591,085
+3,800
+0.2% +$58.1K
VERV
17
DELISTED
Verve Therapeutics
VERV
$51.7M 2.01%
1,505,126
-328,421
-18% -$10.5M
RGNX icon
18
Regenxbio
RGNX
$557M
$50.7M 1.97%
1,917,212
-87,451
-4% -$2.59M
VTYX
19
DELISTED
Ventyx Biosciences
VTYX
$47.7M 1.85%
+1,365,000
New +$30.2M
IMGN
20
DELISTED
Immunogen Inc
IMGN
$40.9M 1.58%
8,548,145
-592,900
-6% -$3.13M
NRIX icon
21
Nurix Therapeutics
NRIX
$2.36B
$39.2M 1.52%
3,006,684
– –
ADCT icon
22
ADC Therapeutics
ADCT
$160M
$36.2M 1.4%
7,512,029
– –
ZYME icon
23
Zymeworks
ZYME
$1.75B
$35.5M 1.38%
5,765,818
+1,930,000
+50% +$11.6M
PEN icon
24
Penumbra
PEN
$12.5B
$33.9M 1.31%
+178,792
New +$28.7M
RPTX
25
DELISTED
Repare Therapeutics
RPTX
$32.6M 1.26%
2,684,396
-36,600
-1% -$471K
1
2 3 4

Similar funds

ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
KP
Keel Point Huntsville, Alabama $1.51B AUM 20.06% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.51B AUM 25.86% 1-Year Est. Return
FCM
Fairholme Capital Management South Miami, Florida $1.51B AUM 28.27% 1-Year Est. Return
SCM
SG Capital Management Chicago, Illinois $1.51B AUM 49.98% 1-Year Est. Return
PP
PDS Planning Dublin, Ohio $1.52B AUM 18.08% 1-Year Est. Return
AM
Ares Management Los Angeles, California $1.52B AUM 12.97% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return

Redmile Group's Q3 2022 Portfolio in Review

As of Q3 2022, Redmile Group held 78 positions worth $2.58B, down 1.6% from $2.62B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Redmile Group withdrew a net $216M in Q3 2022, closing 8 positions and reducing 27 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $151M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Redmile Group opened a new position in Stryker worth $31.9M.

  • Redmile Group's largest Q3 2022 buy was Stryker: 157,321 shares worth $31.9M.
  • Redmile Group added most to Pliant Therapeutics in Q3 2022, an estimated $27.5M increase.
  • Redmile Group's biggest Q3 2022 reduction was argenx, cutting an estimated $39.2M.
  • Redmile Group fully exited Seagen Inc. Common Stock in Q3 2022, selling an estimated $151M.
  • Redmile Group's ten largest holdings make up 48% of its $2.58B portfolio in Q3 2022.
  • Redmile Group opened 7 new positions and closed 8 in Q3 2022.
  • Redmile Group's portfolio value fell 1.6% quarter-over-quarter to $2.58B.

Based on Redmile Group's 13F filing for Q3 2022, filed 14 Nov 2022.